Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Northern Trust Corp raised its holdings in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 21.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 245,523 shares of the company's stock after buying an additional 42,923 shares during the period. Northern Trust Corp owned about 0.83% of Dianthus Therapeutics worth $5,352,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MetLife Investment Management LLC increased its stake in Dianthus Therapeutics by 3.1% in the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock worth $313,000 after purchasing an additional 433 shares during the period. Invesco Ltd. grew its holdings in shares of Dianthus Therapeutics by 7.4% in the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after purchasing an additional 790 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock worth $210,000 after buying an additional 814 shares during the period. Barclays PLC raised its holdings in Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company's stock valued at $933,000 after buying an additional 1,082 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Dianthus Therapeutics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock valued at $3,641,000 after buying an additional 1,092 shares during the period. 47.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DNTH. Robert W. Baird reduced their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Guggenheim reissued a "buy" rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $53.00.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock traded up $0.06 during trading on Monday, hitting $18.42. The company's stock had a trading volume of 234,992 shares, compared to its average volume of 273,728. Dianthus Therapeutics, Inc. has a 52 week low of $13.37 and a 52 week high of $32.27. The company has a market capitalization of $592.39 million, a PE ratio of -7.37 and a beta of 1.48. The company has a fifty day simple moving average of $19.09 and a two-hundred day simple moving average of $21.65.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.04. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.81 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.